Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on recommending the designation of its lead molecule PBT434 for the treatment of Multiple System Atrophy (MSA) as an orphan medicinal product to the European Commission (EC). Following ...
Highlights: Results of Phase 1 Clinical Trials for lead compound PBT434 announced Presentation of clinical trial data at the 2019 International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in France Presentation at the Janney Healthcare conference in New York Cash balance of $10.7M Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the ...
Alterity PBT434 Poster – MDS 2019 Congress
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), presents a poster today titled: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation at the 2019 International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Nice, France. The poster will present findings from the completed ...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is participating in the Janney Healthcare Conference in New York 9-10th September. The event will be attended by major US and European institutional investors, as well as Janney’s largest private client advisors. Dr David Stamler, Alterity’s Chief Medical Officer, will be presenting at the ...
XBRL 30 June 2019 filed with the SEC
Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve concentrations in the brain comparable with other test results Presentation of clinical trial data at the American Academy of Neurology Life Biosciences leads investment round raising an initial A$11.44M during the quarter Name change to Alterity ...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has successfully completed its Phase 1 study of PBT434, a novel, orally bioavailable small molecule inhibitor of alpha-synuclein aggregation. Alpha-synuclein, when aggregated in the brain, is a pathological hallmark of Parkinsonian conditions and is considered an important biologic target for ...
On June 6 2019, Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, participated in the Finance News Network Investor event in Sydney. The presentation included the company’s lead drug candidate, the potential applications for the drug and the breadth of the market. The presentation is now available to view here.
Receive news from Alterity Therapeutics
